Insilico Medicine � MAT2A Inhibitor (Cancer treatment)

This drug is a small molecule inhibitor of MAT2A, an enzyme essential in metabolism and epigenetics. MAT2A is a promising therapeutic strategy for cancers with MTAP deletion (MTAP-/-), a condition that frequently occurs in multiple types of cancers and is associated with poor prognosis. The drug aims to reduce the level of SAM, affecting mRNA splicing and inducing DNA damage, and demonstrates a selective anti-proliferative effect on MTAP-/- cancer cells.